EA201791366A1 - Антитела к c5 и способы их применения - Google Patents

Антитела к c5 и способы их применения

Info

Publication number
EA201791366A1
EA201791366A1 EA201791366A EA201791366A EA201791366A1 EA 201791366 A1 EA201791366 A1 EA 201791366A1 EA 201791366 A EA201791366 A EA 201791366A EA 201791366 A EA201791366 A EA 201791366A EA 201791366 A1 EA201791366 A1 EA 201791366A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
antibodies
describes
antibody
present
Prior art date
Application number
EA201791366A
Other languages
English (en)
Inventor
Ёсинао Руике
Дзендзиро Сампей
Original Assignee
Чугаи Сейяку Кабусики Кайся
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чугаи Сейяку Кабусики Кайся filed Critical Чугаи Сейяку Кабусики Кайся
Publication of EA201791366A1 publication Critical patent/EA201791366A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rehabilitation Therapy (AREA)

Abstract

Задачей изобретения является создание антител к С5 и разработка способов их применения. В заявке описаны антитела к С5 и способы их применения. В некоторых вариантах осуществления изобретения выделенное антитело к С5, предлагаемое в настоящем изобретении, связывается с эпитопом в бета-цепи С5 с более высокой аффинностью при нейтральном рН, чем при кислом рН. В заявке описаны также выделенные нуклеиновые кислоты, кодирующие антитело к С5, предлагаемое в настоящем изобретении. В заявке описаны также клетки-хозяева, которые содержат нуклеиновую кислоту, предлагаемую в настоящем изобретении. В заявке описан также способ получения антитела, включающий культивирование клетки-хозяина, предлагаемой в настоящем изобретении, в результате чего получают антитело. В заявке описан также способ получения антитела к С5, включающий иммунизацию животного полипептидом, который содержит MG1-MG2-домен бета-цепи С5. Антитела к С5, предлагаемые в настоящем изобретении, можно применять в качестве лекарственного средства.
EA201791366A 2014-12-19 2015-12-18 Антитела к c5 и способы их применения EA201791366A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014257647 2014-12-19
PCT/JP2015/006321 WO2016098356A1 (en) 2014-12-19 2015-12-18 Anti-c5 antibodies and methods of use

Publications (1)

Publication Number Publication Date
EA201791366A1 true EA201791366A1 (ru) 2018-02-28

Family

ID=56126263

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791366A EA201791366A1 (ru) 2014-12-19 2015-12-18 Антитела к c5 и способы их применения

Country Status (28)

Country Link
US (5) US9765135B2 (ru)
EP (2) EP3233921B1 (ru)
JP (2) JP6174782B2 (ru)
KR (3) KR102515796B1 (ru)
CN (2) CN113045650A (ru)
AR (1) AR103162A1 (ru)
AU (1) AU2015365167B2 (ru)
BR (1) BR112017011235A2 (ru)
CA (1) CA2967554A1 (ru)
CL (2) CL2017001585A1 (ru)
CO (1) CO2017006651A2 (ru)
CR (1) CR20170251A (ru)
EA (1) EA201791366A1 (ru)
ES (1) ES2899894T3 (ru)
HR (1) HRP20211934T1 (ru)
HU (1) HUE056489T2 (ru)
LT (1) LT3233921T (ru)
MX (1) MX2017007616A (ru)
MY (1) MY183415A (ru)
PH (1) PH12017501114A1 (ru)
PL (1) PL3233921T3 (ru)
PT (1) PT3233921T (ru)
RS (1) RS62749B1 (ru)
RU (1) RU2746356C2 (ru)
SG (2) SG10201710322VA (ru)
SI (1) SI3233921T1 (ru)
TW (3) TWI617580B (ru)
WO (1) WO2016098356A1 (ru)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
HUE029635T2 (en) 2007-09-26 2017-03-28 Chugai Pharmaceutical Co Ltd A method for modifying an isoelectric point of an antibody by amino acid substitution in CDR
DK2708559T3 (en) 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
TWI812066B (zh) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
KR20230005405A (ko) 2011-02-25 2023-01-09 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체
CN110680920A (zh) 2011-09-30 2020-01-14 中外制药株式会社 诱导针对靶抗原的免疫应答的抗原结合分子
TW201817744A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP3939996A1 (en) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
KR20140100532A (ko) 2011-11-30 2014-08-14 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
TWI797443B (zh) 2012-05-30 2023-04-01 日商中外製藥股份有限公司 抗原結合分子之篩選或製造方法
EP3721900A1 (en) 2012-08-24 2020-10-14 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-specific fc region variant
TWI636062B (zh) 2013-04-02 2018-09-21 中外製藥股份有限公司 Fc region variant
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
PL3233921T3 (pl) 2014-12-19 2022-01-10 Chugai Seiyaku Kabushiki Kaisha Przeciwciała anty-c5 i sposoby ich stosowania
TWI779010B (zh) 2014-12-19 2022-10-01 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
EP3253778A1 (en) 2015-02-05 2017-12-13 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
TW201718014A (zh) 2015-10-12 2017-06-01 諾華公司 C5抑制劑於移植相關微血管病之用途
FI3390442T3 (fi) * 2015-12-18 2023-11-10 Chugai Pharmaceutical Co Ltd Anti-C5-vasta-aineita ja käyttömenetelmiä
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
US20190023775A1 (en) 2016-01-11 2019-01-24 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
AU2017264754A1 (en) 2016-05-10 2018-12-13 Genentech, Inc. Methods of decreasing trisulfide bonds during recombinant production of polypeptides
SI3468990T1 (sl) 2016-06-14 2024-07-31 Regeneron Pharmaceuticals, Inc. Protitelesa proti-C in njihove uporabe
CN109312326B (zh) * 2016-06-17 2022-09-09 中外制药株式会社 抗-c5抗体及使用方法
KR102538749B1 (ko) 2016-08-05 2023-06-01 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
WO2018044858A2 (en) * 2016-08-29 2018-03-08 The Cleveland Clinic Foundation C5 immunization for autologous anti-c5 antibody production
EP3554543A4 (en) * 2016-12-16 2020-09-02 Samsung Bioepis Co., Ltd. STABLE AQUEOUS COMPOSITION OF ANTI-C5 ANTIBODIES
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
KR20230043247A (ko) * 2017-01-31 2023-03-30 추가이 세이야쿠 가부시키가이샤 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
EA201992091A1 (ru) * 2017-03-06 2020-02-04 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Анти-c5 антитела и их применение
ES2967965T3 (es) 2017-05-22 2024-05-06 Alexion Pharma Inc Dosis y administración de anticuerpos anti-C5 para el tratamiento de enteropatía pierde-proteínas en pacientes
CA3069756A1 (en) 2017-07-27 2019-01-31 Alexion Pharmaceuticals, Inc. High concentration anti-c5 antibody formulations
BR112020008182A2 (pt) 2017-10-26 2020-10-27 Alexion Pharmaceuticals, Inc. dosagem e administração de anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna (hpn) e síndrome hemolítica urêmica atípica (shua)
WO2019098212A1 (en) 2017-11-14 2019-05-23 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
MX2020006113A (es) 2017-12-13 2020-08-24 Regeneron Pharma Combinaciones de anticuerpos anti-c5 y usos de las mismas.
JP2021519073A (ja) 2018-03-29 2021-08-10 ジェネンテック， インコーポレイテッド 哺乳動物細胞におけるラクトジェニック活性の制御
US20200378986A1 (en) * 2018-05-24 2020-12-03 Sigma-Aldrich Co. Llc Quantitative analysis of proteins
EP3802593B1 (en) 2018-05-31 2024-09-11 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
US20210332147A1 (en) 2018-06-04 2021-10-28 Alexion Pharmaceuticals, Inc. DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS) IN PEDIATRIC PATIENTS
US20210122806A1 (en) 2018-06-28 2021-04-29 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
HRP20240823T1 (hr) * 2018-08-01 2024-09-27 Chugai Seiyaku Kabushiki Kaisha Farmaceutski pripravak, namijenjen upotrebi u liječenju ili sprječavanju bolesti povezane s c5 i postupak liječenja ili sprječavanja bolesti povezane s c5
KR20210055742A (ko) * 2018-09-06 2021-05-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 인간화된 항-c5 항체 및 이의 용도
US20220056115A1 (en) * 2018-09-17 2022-02-24 Kyoto University Administration of an anti-c5 agent for treatment of hepatic injury or failure
US20200095307A1 (en) 2018-09-21 2020-03-26 Alexion Pharmaceuticals, Inc. Compositions and methods for the treatment of neuromyelitis optica
US20210388070A1 (en) 2018-10-30 2021-12-16 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
BR112021008063A2 (pt) 2018-10-30 2021-08-10 Alexion Pharmaceuticals, Inc. dosagem subcutânea e administração de anticorpos anti-c 5 para tratamento de hemoglobinúria paroxística noturna (pnh)
CA3127797A1 (en) 2019-01-25 2020-07-30 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus)
AU2020223298A1 (en) 2019-02-14 2021-09-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of generalized myasthenia gravis
WO2020213706A1 (en) * 2019-04-19 2020-10-22 Chugai Seiyaku Kabushiki Kaisha Antibodies and compositions for use in detecting or capturing a polypeptide in a sample, and methods for detecting or capturing a polypeptide in a sample
CA3137397A1 (en) 2019-04-19 2020-10-22 Chugai Seiyaku Kabushiki Kaisha Chimeric receptor that recognizes engineered site in antibody
US20220227851A1 (en) 2019-05-24 2022-07-21 Alexion Pharmaceuticals, Inc. Methods of treating vitiligo using an anti-c5 antibody
KR20210016333A (ko) 2019-07-31 2021-02-15 에프. 호프만-라 로슈 아게 항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생
KR20240001329A (ko) 2019-07-31 2024-01-03 에프. 호프만-라 로슈 아게 항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생
WO2021067526A1 (en) 2019-10-02 2021-04-08 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
WO2021118999A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Anti-c5 antibody for the treatment of neuromyelitis optica spectrum disorder
EP4081805A1 (en) 2019-12-23 2022-11-02 Alexion Pharmaceuticals, Inc. Methods of treating pregnancy-associated atypical hemolytic uremic syndrome using an anti-c5 antibody
CN111234016B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的全人源单克隆抗体及应用
CN115315512A (zh) 2020-03-26 2022-11-08 基因泰克公司 具有降低的宿主细胞蛋白质的经修饰的哺乳动物细胞
BR112022017526A2 (pt) 2020-03-31 2022-10-18 Chugai Pharmaceutical Co Ltd Método para produzir moléculas de ligação de antígeno multiespecíficas
CN113563467A (zh) * 2020-04-28 2021-10-29 上海普铭生物科技有限公司 针对人补体蛋白c5的抗体及其应用
BR112022022980A2 (pt) 2020-05-12 2022-12-20 Alexion Pharma Inc Uso de inibidores de fator d de complemento sozinhos ou em combinação com anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna
WO2021231720A1 (en) 2020-05-15 2021-11-18 Alexion Pharmaceuticals, Inc. Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease
AU2021281445A1 (en) * 2020-05-29 2022-12-22 Amgen Inc. Antibody formulations and uses thereof
JP2023533682A (ja) 2020-06-24 2023-08-04 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体関連病態の処置用抗ｃ５抗体の皮下（ｓｃ）投与
EP4172192A1 (en) 2020-06-24 2023-05-03 Genentech, Inc. Apoptosis resistant cell lines
EP4172200A1 (en) * 2020-06-24 2023-05-03 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing c5a and uses thereof
WO2022011086A1 (en) * 2020-07-09 2022-01-13 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treating paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
IL300115A (en) 2020-08-13 2023-03-01 Alexion Pharma Inc Dosage and Administration of ANTI-C5 Antibodies for Hematopoietic Stem Cell Transplantation Treatment (HSCT-TMA)
JP2023539201A (ja) 2020-08-28 2023-09-13 ジェネンテック， インコーポレイテッド 宿主細胞タンパク質のＣＲＩＳＰＲ／Ｃａｓ９マルチプレックスノックアウト
CA3173003A1 (en) 2020-09-21 2022-03-24 Nader Najafian Dosage and administration of anti-c5 antibodies for treating c5-mediated glomerular nephritis (gn), including lupus nephritis (ln) and/or iga nephropathy (igan)
JP2023548046A (ja) 2020-10-23 2023-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃ５抗体を使用する、補体障害を有する患者の処置方法
AU2022210283A1 (en) 2021-01-22 2023-08-03 Alexion Pharmaceuticals, Inc. Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody
IL307501A (en) 2021-04-19 2023-12-01 Hoffmann La Roche Modified mammalian cells
EP4341385A1 (en) 2021-05-21 2024-03-27 Genentech, Inc. Modified cells for the production of a recombinant product of interest
WO2022255440A1 (en) 2021-06-04 2022-12-08 Chugai Seiyaku Kabushiki Kaisha Anti-ddr2 antibodies and uses thereof
WO2022265915A1 (en) 2021-06-14 2022-12-22 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treating dermatomyositis (dm)
TW202317627A (zh) * 2021-06-25 2023-05-01 日商中外製藥股份有限公司 抗ctla-4抗體
WO2023287991A1 (en) 2021-07-14 2023-01-19 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis
WO2023023220A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
TW202346339A (zh) 2022-04-04 2023-12-01 瑞士商赫孚孟拉羅股份公司 藉由使用抗ｃ５抗體克羅伐單抗之治療或預防格林－巴利症候群之劑量及投予方案
TW202404632A (zh) 2022-04-04 2024-02-01 瑞士商赫孚孟拉羅股份公司 用於藉由使用抗ｃ５抗體克羅伐單抗治療或預防格林－巴利症候群之劑量及投予方案
WO2023215443A1 (en) * 2022-05-04 2023-11-09 Alexion Pharmaceuticals, Inc. Compositions and methods for the treatment of neuromyelitis optica spectrum disorder
TW202426048A (zh) 2022-09-06 2024-07-01 美商阿雷希昂製藥公司 用於治療造血幹細胞移植相關血栓性（ｈｓｃｔ－ｔｍａ）的抗ｃ５抗體的補充劑量和投與
WO2024054436A1 (en) 2022-09-06 2024-03-14 Alexion Pharmaceuticals, Inc. Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
TW202423479A (zh) 2022-09-28 2024-06-16 美商阿雷希昂製藥公司 用於預防或最小化患有慢性腎病的患者中的心臟手術相關急性腎損傷（csa-aki）和/或隨後的主要不良腎事件（make）的抗c5抗體之劑量及投與

Family Cites Families (276)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5144499B1 (ru) 1970-08-29 1976-11-29
JPS5824836B2 (ja) 1974-10-14 1983-05-24 ノウミボウサイコウギヨウ カブシキガイシヤ カサイナドノツウホウソウチ
US4769320A (en) 1982-07-27 1988-09-06 New England Medical Center Hospitals, Inc. Immunoassay means and methods useful in human native prothrombin and human abnormal prothorombin determinations
ES521371A0 (es) 1982-04-12 1984-05-16 Hybritech Inc Un procedimiento para la purificacion de un anticuerpo.
US4689299A (en) 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
JPS6350741A (ja) 1986-08-20 1988-03-03 Nippon Tectron Co Ltd 蛍光偏光分析装置
JPH06104071B2 (ja) 1986-08-24 1994-12-21 財団法人化学及血清療法研究所 第▲ｉｘ▼因子コンホメ−シヨン特異性モノクロ−ナル抗体
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5202253A (en) 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
CA2006684C (en) 1988-12-30 1996-12-17 Charles T. Esmon Monoclonal antibody against protein c
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
JPH0636741B2 (ja) 1989-11-08 1994-05-18 帝人株式会社 ヒト・プロテインｃの分離方法
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2075927A1 (en) 1990-02-16 1991-08-17 Victor A. Raso Hybrid reagents capable of selectively releasing molecules into cells
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DK0628639T3 (da) 1991-04-25 2000-01-24 Chugai Pharmaceutical Co Ltd Rekonstitueret humant antistof mod human interleukin-6-receptor
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
CA2162497A1 (en) 1993-06-10 1994-12-22 Sheila Connelly Adenoviral vectors for treatment of hemophilia
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
IL107742A0 (en) 1993-11-24 1994-02-27 Yeda Res & Dev Chemically-modified binding proteins
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
ES2384222T3 (es) 1994-10-07 2012-07-02 Chugai Seiyaku Kabushiki Kaisha Inhibición del crecimiento anómalo de células sinoviales utilizando un antagonista de IL-6 como principio activo
DE4436561C1 (de) 1994-10-13 1996-03-14 Deutsche Spezialglas Ag Verfahren zur Veränderung der Durchbiegung von anodisch gebondeten flächigen Verbundkörpern aus Glas und Metall oder Halbleitermaterialien
CN100350973C (zh) 1994-10-21 2007-11-28 岸本忠三 用于治疗il－6产生所致疾病的药物组合物
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US6485943B2 (en) 1995-01-17 2002-11-26 The University Of Chicago Method for altering antibody light chain interactions
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5830478A (en) 1995-06-07 1998-11-03 Boston Biomedical Research Institute Method for delivering functional domains of diphtheria toxin to a cellular target
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
AU720232B2 (en) 1996-07-19 2000-05-25 Amgen, Inc. Analogs of cationic proteins
US5990286A (en) 1996-12-18 1999-11-23 Techniclone, Inc. Antibodies with reduced net positive charge
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US7365166B2 (en) 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
AU7132798A (en) 1997-04-17 1998-11-11 Amgen, Inc. Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ES2293691T3 (es) 1997-10-03 2008-03-16 Chugai Seiyaku Kabushiki Kaisha Anticuerpo humano natural.
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
ATE512225T1 (de) 1998-04-03 2011-06-15 Chugai Pharmaceutical Co Ltd Humanisierter antikörper gegen den menschlichen gewebefaktor (tf) und verfahren für die konstruktion eines solchen humanisierten antikörpers.
US20030175884A1 (en) 2001-08-03 2003-09-18 Pablo Umana Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
US6475718B2 (en) 1998-09-08 2002-11-05 Schering Aktiengesellschaft Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
MXPA01005515A (es) 1998-12-01 2003-07-14 Protein Design Labs Inc Anticuerpos humanizados para gamma-interferon.
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
NZ517906A (en) 1999-10-04 2003-01-31 Medicago Inc Cloning of genomic sequences encoding nitrite reductase (NiR) for use in regulated expression of foreign genes in host plants
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
SE9903895D0 (sv) 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
IL149809A0 (en) 1999-12-15 2002-11-10 Genentech Inc Shotgun scanning, a combinatorial method for mapping functional protein epitopes
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
WO2001082899A2 (en) 2000-05-03 2001-11-08 Mbt Munich Biotechnology Ag Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
WO2002002641A1 (en) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
EA013224B1 (ru) 2000-10-06 2010-04-30 Киова Хакко Кирин Ко., Лтд. Клетки, продуцирующие композиции антител
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP2113516B1 (en) 2000-10-10 2014-05-21 Genentech, Inc. Antibodies against C5 inhibiting type II endothelial cell activation
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1916303B1 (en) 2000-11-30 2013-02-27 Medarex, Inc. Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
KR100927670B1 (ko) 2001-04-13 2009-11-20 바이오겐 아이덱 엠에이 인코포레이티드 Ｖｌａ-1에 대한 항체들
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
PT1411118E (pt) 2001-06-22 2008-12-09 Chugai Pharmaceutical Co Ltd Inibidores da proliferação celular contendo um anticorpo anti-glipicano 3
US20040161741A1 (en) 2001-06-30 2004-08-19 Elazar Rabani Novel compositions and processes for analyte detection, quantification and amplification
EP1425042B2 (en) 2001-08-17 2016-02-10 Genentech, Inc. Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b
US20030049203A1 (en) 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
BRPI0214168B8 (pt) 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US6684637B2 (en) 2002-01-25 2004-02-03 Sunpower, Inc. Parallel slot heat exchanger
US20030224397A1 (en) 2002-02-11 2003-12-04 Genentech, Inc. Antibody variants with faster antigen association rates
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
JP4832719B2 (ja) 2002-04-09 2011-12-07 協和発酵キリン株式会社 ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
WO2003085118A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede de production de composition anticorps
JP4628679B2 (ja) 2002-04-09 2011-02-09 協和発酵キリン株式会社 Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
WO2003084569A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition anticorps
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
AU2003256266A1 (en) 2002-06-12 2003-12-31 Genencor International, Inc. Methods and compositions for milieu-dependent binding of a targeted agent to a target
CA2489022C (en) 2002-06-12 2012-10-16 Genencor International, Inc. Methods for improving a binding characteristic of a molecule
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
AU2003264009A1 (en) 2002-08-15 2004-03-03 Epitomics, Inc. Humanized rabbit antibodies
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP2301966A1 (en) 2002-12-16 2011-03-30 Genentech, Inc. Immunoglobulin variants and uses thereof
CA2510003A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
CA2515081A1 (en) 2003-02-07 2004-08-19 Protein Design Labs, Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
CA2517396A1 (en) 2003-02-28 2005-03-10 Antigenics Inc. Use of lectins to promote oligomerization of glycoproteins and antigenic molecules
AU2004215653B2 (en) 2003-02-28 2011-03-17 Lonza Biologics Plc. Antibody purification by protein A and ion exchange chromatography
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
ES2537738T3 (es) 2003-06-05 2015-06-11 Genentech, Inc. Terapia de combinación para trastornos de células B
US20050152894A1 (en) 2003-09-05 2005-07-14 Genentech, Inc. Antibodies with altered effector functions
CA2542046A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
US20070134759A1 (en) 2003-10-09 2007-06-14 Harue Nishiya Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
LT2348051T (lt) 2003-11-05 2019-02-25 Roche Glycart Ag Cd20 antikūnai su padidintu fc receptoriaus prisijungimo giminingumu ir efektorine funkcija
RS50516B (sr) 2003-11-05 2010-05-07 Ares Trading S.A. Prečišćavanje il-18 vezujućeg proteina
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
PT1711207E (pt) 2003-12-10 2013-02-13 Medarex Inc Anticorpos alfa interferão e seus usos
PE20051053A1 (es) 2004-01-09 2005-12-12 Pfizer ANTICUERPOS CONTRA MAdCAM
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
BRPI0506679A (pt) 2004-02-11 2007-05-15 Warner Lambert Co métodos de tratar osteoartrite com antagonistas de il-6
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP2357201B1 (en) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
WO2005112564A2 (en) 2004-04-15 2005-12-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Germline and sequence variants of humanized antibodies and methods of making and using them
KR100620554B1 (ko) 2004-06-05 2006-09-06 한국생명공학연구원 Ｔａｇ-72에 대한 인간화 항체
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
EP1771205B1 (en) 2004-06-18 2016-10-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US20060019342A1 (en) 2004-06-25 2006-01-26 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
SI2471813T1 (sl) 2004-07-15 2015-03-31 Xencor, Inc. Optimirane Fc variante
EP2213683B1 (en) 2004-08-04 2013-06-05 Mentrik Biotech, LLC Variant Fc regions
MX2007002883A (es) 2004-09-13 2007-06-15 Macrogenics Inc Anticuerpos humanizados contra el virus de nilo occidental y usos terapeuticos y profilacticos del mismo.
US20080233131A1 (en) 2004-09-14 2008-09-25 Richard John Stebbings Vaccine
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US20090061485A1 (en) 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
KR20070115871A (ko) 2004-12-23 2007-12-06 노보 노르디스크 에이/에스 항체 결합 친화 리간드
GB0502358D0 (en) 2005-02-04 2005-03-16 Novartis Ag Organic compounds
EP1870459B1 (en) 2005-03-31 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
CA2603264C (en) 2005-04-08 2017-03-21 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
CA2607281C (en) 2005-05-05 2023-10-03 Duke University Anti-cd19 antibody therapy for autoimmune disease
SI1915397T1 (sl) 2005-08-19 2015-05-29 Wyeth Llc Antagonistična protitelesa proti GDF-8 in uporabe pri zdravljenju ALS in drugih obolenj, povezanih z GDF-8
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
WO2007060411A1 (en) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
WO2007076200A2 (en) 2005-11-28 2007-07-05 Medimmune, Inc. Antagonists of hmgb1 and/or rage and methods of use thereof
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
JP5249043B2 (ja) * 2005-12-12 2013-07-31 エーシー イミューン ソシエテ アノニム 治療ワクチン
EP1971366B1 (en) 2005-12-29 2014-07-30 Janssen Biotech, Inc. Human anti-il-23 antibodies, compositions, methods and uses
RS53864B1 (en) 2006-03-02 2015-08-31 Alexion Pharmaceuticals, Inc. EXTENDING ALOGRAPHIC SURVIVAL BY INHIBITING COMPLEMENT ACTIVITIES
SI1991275T1 (sl) 2006-03-08 2015-03-31 Archemix Llc Komplement vezavni aptameri in sredstva proti C5, uporabni pri zdravljenju očesnih motenj
WO2007106585A1 (en) 2006-03-15 2007-09-20 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
KR20150006085A (ko) 2006-04-05 2015-01-15 애브비 바이오테크놀로지 리미티드 항체 정제
AR060871A1 (es) 2006-05-09 2008-07-16 Genentech Inc Union de polipeptidos con supercontigos optimizados
AU2007255753B2 (en) 2006-06-08 2013-01-17 Chugai Seiyaku Kabushiki Kaisha Preventive or remedy for inflammatory disease
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
EP2695896B1 (en) 2006-10-06 2018-08-22 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Prevention of tissue ischemia, related methods and compositions
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
KR20100015773A (ko) * 2007-03-22 2010-02-12 노파르티스 아게 Ｃ５ 항원 및 그의 용도
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
BRPI0813954A2 (pt) 2007-06-29 2020-10-06 Quest Diagnostics Investments Incorporated análise de aminoácidos no fluido do corpo através de cromatografia líquida-espectometria de massa
HUE029635T2 (en) 2007-09-26 2017-03-28 Chugai Pharmaceutical Co Ltd A method for modifying an isoelectric point of an antibody by amino acid substitution in CDR
SG193868A1 (en) 2007-09-26 2013-10-30 Chugai Pharmaceutical Co Ltd Modified antibody constant region
CN101939425B (zh) 2007-09-26 2014-05-14 中外制药株式会社 抗il-6受体抗体
NZ584769A (en) 2007-09-28 2011-09-30 Chugai Pharmaceutical Co Ltd Anti-glypican-3 antibody having improved kinetics in plasma
EP2235058A2 (en) 2007-12-21 2010-10-06 Amgen, Inc Anti-amyloid antibodies and uses thereof
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
DK2708559T3 (en) 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
JP2011519279A (ja) 2008-05-01 2011-07-07 アムジエン・インコーポレーテツド 抗ヘプシジン抗体及び使用の方法
AU2009257370B2 (en) 2008-06-14 2015-01-22 Auris Health, Inc. System and method for delivering energy to tissue
MX2011001371A (es) 2008-08-05 2011-06-16 Novartis Ag Composiciones y metodos para anticuerpos que se dirigen a la proteina de complementos c5.
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US20100292443A1 (en) 2009-02-26 2010-11-18 Sabbadini Roger A Humanized platelet activating factor antibody design using anti-lipid antibody templates
RU2012102021A (ru) 2009-06-23 2013-07-27 Алексион Фармасьютикалз, Инк. Биспецифические антитела, которые связываются с белками комплемента
CN101875696B (zh) * 2009-11-11 2012-02-08 中国人民解放军军事医学科学院生物工程研究所 一种抗体及其制备方法与应用
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
CN102971342B (zh) 2010-01-28 2016-08-03 Ab生物科学公司 亲和力降低的新抗体和制备所述抗体的方法
WO2011109338A1 (en) * 2010-03-01 2011-09-09 Alexion Pharmaceuticals Inc. Methods and compositions for treating degos' disease
KR20120138241A (ko) * 2010-03-11 2012-12-24 화이자 인코포레이티드 ｐＨ 의존성 항원 결합을 갖는 항체
TW201206466A (en) * 2010-03-11 2012-02-16 Rinat Neuroscience Corp Antibodies with pH dependent antigen binding
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
WO2011137362A1 (en) 2010-04-30 2011-11-03 Rother Russell P Antibodies having reduced immunogenicity in a human
TWI812066B (zh) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
CA2822288A1 (en) 2010-12-22 2012-06-28 Medimmune, Llc Anti-c5/c5a/c5adesr antibodies and fragments
KR20230005405A (ko) 2011-02-25 2023-01-09 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체
RS58765B1 (sr) 2011-05-21 2019-06-28 Macrogenics Inc Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3
WO2012177653A2 (en) * 2011-06-20 2012-12-27 St. Louis University Targeting the neuromuscular junction for treatment
EP3939996A1 (en) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP2765192A4 (en) 2011-10-05 2015-04-15 Chugai Pharmaceutical Co Ltd ANTIGEN BINDING MOLECULE FOR PROMOTING THE PLASMA CLAIR OF AN ANTIGEN COMPRISING A SACCHARIDIC CHAIN TYPE RECEPTOR BINDING DOMAIN
KR20140100532A (ko) 2011-11-30 2014-08-14 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
CA2865158C (en) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
BR112014022855A2 (pt) 2012-03-16 2017-07-18 Regeneron Pharma animal não humano geneticamente modificado, mamífero geneticamente modificado, e, método para fabricar um animal não humano
RU2644684C2 (ru) * 2012-03-16 2018-02-13 Регенерон Фармасьютикалз, Инк. Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения
AU2013237929B2 (en) * 2012-03-29 2017-09-14 Novimmune S.A. Anti-TLR4 antibodies and uses thereof
TWI619729B (zh) * 2012-04-02 2018-04-01 再生元醫藥公司 抗－ｈｌａ－ｂ*２７抗體及其用途
ES2856272T3 (es) 2012-05-30 2021-09-27 Chugai Pharmaceutical Co Ltd Molécula de unión a antígenos para eliminar antígenos agregados
MX363213B (es) * 2012-08-13 2019-03-15 Regeneron Pharma Anticuerpos anti-pcsk9 con características de unión dependientes del ph.
US9133269B2 (en) 2012-08-24 2015-09-15 Anaptysbio, Inc. Humanized antibodies directed against complement protein C5
TW201418707A (zh) 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
BR112015018438A2 (pt) 2013-01-31 2017-07-18 Seoul Nat Univ R&Db Foundation anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
WO2014144080A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
US9321686B2 (en) 2013-03-15 2016-04-26 Forta Corporation Reinforcement fiber coating compositions, methods of making and treating, and uses for improved adhesion to asphalt and portland cement concrete
EP3473272A1 (en) 2013-03-29 2019-04-24 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
TWI636062B (zh) 2013-04-02 2018-09-21 中外製藥股份有限公司 Fc region variant
US20160184391A1 (en) 2013-08-16 2016-06-30 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
JP6382641B2 (ja) 2013-09-11 2018-08-29 株式会社東芝 非水電解質電池及び非水電解質電池の製造方法
EP3107935B1 (en) 2014-02-20 2020-06-24 Allergan, Inc. Complement component c5 antibodies
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
JP2016024424A (ja) 2014-07-24 2016-02-08 株式会社リコー 情報処理システム、情報処理装置、情報処理方法、及びプログラム
PL3233921T3 (pl) 2014-12-19 2022-01-10 Chugai Seiyaku Kabushiki Kaisha Przeciwciała anty-c5 i sposoby ich stosowania
JP2018511557A (ja) 2015-01-22 2018-04-26 中外製薬株式会社 ２種以上の抗ｃ５抗体の組み合わせおよび使用方法
EP3253778A1 (en) 2015-02-05 2017-12-13 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
CN107249637A (zh) 2015-02-27 2017-10-13 中外制药株式会社 用于治疗il‑6相关疾病的组合物
EP3277715A2 (en) 2015-03-31 2018-02-07 Alexion Pharmaceuticals, Inc. Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients
WO2016178980A1 (en) 2015-05-01 2016-11-10 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of kindney thansplant
US20180142010A1 (en) 2015-06-26 2018-05-24 Alexion Pharmaceuticals, Inc. Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
TW201718014A (zh) 2015-10-12 2017-06-01 諾華公司 C5抑制劑於移植相關微血管病之用途
FI3390442T3 (fi) 2015-12-18 2023-11-10 Chugai Pharmaceutical Co Ltd Anti-C5-vasta-aineita ja käyttömenetelmiä
US10233252B2 (en) 2015-12-21 2019-03-19 Wisconsin Alumni Research Foundation pH-dependent antibodies targeting the transferrin receptor and methods of use thereof to deliver a therapeutic agent
US20190023775A1 (en) 2016-01-11 2019-01-24 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
EP3408291A1 (en) 2016-01-25 2018-12-05 Shire Human Genetic Therapies, Inc. Anti-c5 antibodies with enhanced ph switch
SI3468990T1 (sl) 2016-06-14 2024-07-31 Regeneron Pharmaceuticals, Inc. Protitelesa proti-C in njihove uporabe
CN109312326B (zh) 2016-06-17 2022-09-09 中外制药株式会社 抗-c5抗体及使用方法
KR20230043247A (ko) 2017-01-31 2023-03-30 추가이 세이야쿠 가부시키가이샤 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
CN110740749A (zh) 2017-03-14 2020-01-31 戊瑞治疗有限公司 在酸性pH下与VISTA结合的抗体
TWI788332B (zh) 2017-03-16 2023-01-01 英商梅迪繆思有限公司 抗-par2抗體及其用途
WO2018184739A1 (en) 2017-04-03 2018-10-11 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of c5a activity
BR112020008182A2 (pt) 2017-10-26 2020-10-27 Alexion Pharmaceuticals, Inc. dosagem e administração de anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna (hpn) e síndrome hemolítica urêmica atípica (shua)
MX2020005547A (es) 2017-12-04 2020-08-20 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
HRP20240823T1 (hr) 2018-08-01 2024-09-27 Chugai Seiyaku Kabushiki Kaisha Farmaceutski pripravak, namijenjen upotrebi u liječenju ili sprječavanju bolesti povezane s c5 i postupak liječenja ili sprječavanja bolesti povezane s c5

Also Published As

Publication number Publication date
SI3233921T1 (sl) 2022-01-31
JP6755217B2 (ja) 2020-09-16
CN107207607B (zh) 2021-05-04
TW201632557A (zh) 2016-09-16
HRP20211934T1 (hr) 2022-03-18
KR102515796B1 (ko) 2023-03-30
RU2017125758A (ru) 2019-01-22
TWI617580B (zh) 2018-03-11
CO2017006651A2 (es) 2017-09-29
PT3233921T (pt) 2021-12-09
CL2021000630A1 (es) 2021-07-30
BR112017011235A2 (pt) 2018-02-06
AR103162A1 (es) 2017-04-19
SG11201607165YA (en) 2016-09-29
RS62749B1 (sr) 2022-01-31
AU2015365167A1 (en) 2017-06-01
KR101838645B1 (ko) 2018-03-14
US10023630B2 (en) 2018-07-17
CR20170251A (es) 2017-07-19
PL3233921T3 (pl) 2022-01-10
US20190062413A1 (en) 2019-02-28
CN113045650A (zh) 2021-06-29
ES2899894T3 (es) 2022-03-15
TW202031897A (zh) 2020-09-01
JP6174782B2 (ja) 2017-08-02
JP2017200489A (ja) 2017-11-09
CL2017001585A1 (es) 2018-12-21
RU2746356C2 (ru) 2021-04-12
TW201809008A (zh) 2018-03-16
PH12017501114A1 (en) 2017-11-27
JP2017509312A (ja) 2017-04-06
US10385122B2 (en) 2019-08-20
EP3981794A1 (en) 2022-04-13
US20200031913A1 (en) 2020-01-30
EP3233921A1 (en) 2017-10-25
MX2017007616A (es) 2017-09-18
US20160176954A1 (en) 2016-06-23
CN107207607A (zh) 2017-09-26
TWI725847B (zh) 2021-04-21
WO2016098356A1 (en) 2016-06-23
HUE056489T2 (hu) 2022-02-28
KR20170092449A (ko) 2017-08-11
RU2017125758A3 (ru) 2019-10-25
LT3233921T (lt) 2021-12-10
EP3233921A4 (en) 2018-07-11
EP3233921B1 (en) 2021-09-29
CA2967554A1 (en) 2016-06-23
SG10201710322VA (en) 2018-02-27
US20180002415A1 (en) 2018-01-04
AU2015365167B2 (en) 2021-07-29
KR20230044338A (ko) 2023-04-03
US9765135B2 (en) 2017-09-19
MY183415A (en) 2021-02-18
KR20180029267A (ko) 2018-03-20
US20240052021A1 (en) 2024-02-15
US11597760B2 (en) 2023-03-07

Similar Documents

Publication Publication Date Title
EA201791366A1 (ru) Антитела к c5 и способы их применения
EA201891410A1 (ru) Антитела к с5 и способы их применения
EA201990018A1 (ru) Антитела к с5 и способы их применения
AR103161A1 (es) Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
HRP20191865T1 (hr) Novi heterodimerni proteini
CL2017001328A1 (es) Anticuerpos heterodimericos que unen cd3 y antígenos tumorales
BR112015023262A2 (pt) anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
BR112017006203A2 (pt) anticorpos isolado, caninizado e monoclonal ou fragmento de ligação ao antígeno dos mesmos, ácido nucleico isolado, vetor de expressão, célula hospedeira, peptídeo antigênico isolado, proteína de fusão, composição farmacêutica, e, método de aumento da atividade de uma célula imune.
MX2017001401A (es) Constructos de anticuerpos de cadena sencilla biespecifica especificos para especies cruzadas optimizadas.
EA201591131A1 (ru) Днк-конструкции антитела и способ их применения
EA201890796A1 (ru) Новое антитело к мезотелину и содержащая его композиция
EA201600252A1 (ru) Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
EA201492101A1 (ru) Антитела против fcrn
BR112015024553A2 (pt) anticorpo multiespecífico, anticorpo isolado, ácido nucleico isolado, célula hospedeira, método de produção de anticorpo, imunoconjugado, formulação farmacêutica, uso de anticorpo e método de tratamento de indivíduos com distúrbio
MX2015012540A (es) Ratón de cadena ligera común.
CN103562403A8 (zh) 识别肿瘤起始细胞的抗体和抗原及其应用
TR201901668T4 (tr) Sınırlı bir immünoglobulin hafif zincir repertuvarını eksprese eden fareler.
EA201690171A1 (ru) Улучшенный способ получения моноклональных антител
EA201600276A1 (ru) Анти-il-17-антитела, способ их получения и способ применения
EA201990894A9 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
BR112017007592A2 (pt) polipeptídeo, composição de polipeptídeos, métodos de produção de polipeptídeo e de detecção de anticorpos, uso de polipeptídeo e kit de reagentes
EA202091596A1 (ru) Антитела к pd-1 и способы лечения
TH154333A (th) โมโนโคลนอลแอนติบอดีที่มีความจำเพาะต่อลำดับกรดอะมิโนที่ 1-30 ของโปรตีน Mig7 และการนำไปใช้
EA201500546A1 (ru) МОНОКЛОНАЛЬНЫЕ АНТИ-D АНТИТЕЛА С ВЫСОКИМ СРОДСТВОМ К НИЗКОАФФИННЫМ Fcgamma РЕЦЕПТОРАМ
EA202090128A3 (ru) Антитела против антигена 2 дендритных клеток крови и их применение